11 February 2025
Coulter Partners places Chief Medical Officer and Head of R&D at Bausch Health

Coulter Partners successfully completed a search assignment for Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”) and is pleased to announce the placement of Jonathan Sadeh M.D., M.Sc., as Executive Vice President, Chief Medical Officer and Head of R&D.
Bausch Health is a global company that develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and international pharmaceuticals.
Jonathan Sadeh brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb, he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles including Senior Vice President and Global Programs Head for Immunology, Cardiovascular and Neuroscience, Immunology Therapeutic Area Head, as well as the China R&D Head. His experience spans leading global R&D programs at major pharmaceutical companies such as Bristol-Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough.
"We are delighted to welcome Jonathan as our new Head of Research and Development," said Thomas J. Appio, Chief Executive Officer at Bausch Health. "His extensive experience and innovative vision will be invaluable as we continue to enhance our pipeline and strive for groundbreaking advancements."
In his new role, Jonathan will be responsible for overseeing the entire R&D process, working closely with Bausch Health’s scientists and engineers. He will set the strategic direction and ensure alignment with their overall goal of enriching lives through a relentless drive to deliver better health outcomes. We are confident that Jonathan will make a significant contribution to the company's success and commitment to being an innovative healthcare company.
----

Jonathan Sadeh, Executive Vice President, Chief Medical Officer and Head of R&D, Bausch Health
Jonathan is a physician-scientist with over 20 years of experience in clinical research and drug development. Prior to Bausch Health, he was at Bristol-Myers Squibb, where he held multiple roles including Senior Vice President and Global Programs Head for Immunology, Cardiovascular and Neuroscience, Immunology Therapeutic Area Head, and China R&D Head. Prior to Bristol-Myers Squibb, he held senior leadership roles at Sanofi, AstraZeneca, and Schering-Plough, where he started his industry career. Jonathan is trained as a pulmonary and critical care physician and began his medical career as an academic researcher at Brigham and Women’s Hospital. He completed his pulmonary and critical care training at Mass General and Brigham and Women’s Hospitals, received a master’s degree in clinical research from Harvard Medical School, and earned his medical degree from the Mount Sinai School of Medicine.
About Bausch Health
For more information, visit www.bauschhealth.com
About Coulter Partners
www.coulterpartners.com
Related
-
Events
German Biotech Days (DBT)
09 April 2025 – 10 April 2025
-
Press Releases
Coulter Partners secures CEO Placement for NeoPhore
23 January 2025
-
Press Releases
Coulter Partners places seasoned life sciences and CRO leader as CEO of Metrion Biosciences
08 January 2025
-
Press Releases
Coulter Partners strengthens Curve Therapeutics’ leadership team with appointment of Chief R&D Officer
03 December 2024